Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

被引：0
|
作者：
Ogata, Yutaka
Akagi, Yoshito
Kakeji, Yoshihiro
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Touyama, Tetsuo
Samura, Hironori
Baba, Hideo
Natsugoe, Shoji
Shirouzu, Kazuo
Tokunaga, Shoji
Maehara, Yoshihiko
机构：
[1] Kurume Univ, Dept Surg, Kurume Med Ctr, Sch Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Dept Surg, Sch Med, Kurume, Fukuoka, Japan
[3] Kyushu Univ, Dept Surg & Sci, Fukuoka, Japan
[4] Nakagami Hosp, Okinawa, Japan
[5] Univ Ryukyus, Dept Surg 1, Nishihara, Okinawa, Japan
[6] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan
[7] Kagashima Univ, Dept Gastrointestinal Surg, Kagoshima, Japan
[8] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：2
相关论文
共 50 条
  • [11] FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study
    Mitsugu Kochi
    Yuji Akiyama
    Tatsuya Aoki
    Ken Hagiwara
    Takao Takahashi
    Katsuji Hironaka
    Futoshi Teranishi
    Fumihiko Osuka
    Masahiro Takeuchi
    Masashi Fujii
    Toshifusa Nakajima
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1097 - 1102
  • [12] First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
    Tsuji, Yasushi
    Satoh, Taroh
    Tsuji, Akihito
    Muro, Kei
    Yoshida, Motoki
    Nishina, Tomohiro
    Nagase, Michitaka
    Komatsu, Yoshito
    Kato, Takeshi
    Miyata, Yoshinori
    Mizutani, Naoko
    Hashigaki, Satoshi
    Lechuga, Maria Jose
    Denda, Tadamichi
    CANCER SCIENCE, 2012, 103 (08) : 1502 - 1507
  • [13] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
    Yutaka Ogata
    Mototsugu Shimokawa
    Takaho Tanaka
    Yasunori Emi
    Eiji Oki
    Hiroshi Saeki
    Noriaki Sadanaga
    Tetsuya Kusumoto
    Tetsuo Touyama
    Masami Kimura
    Hideo Baba
    Yoshito Akagi
    Kazuo Shirouzu
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2016, 21 : 335 - 343
  • [14] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
    Ogata, Yutaka
    Shimokawa, Mototsugu
    Tanaka, Takaho
    Emi, Yasunori
    Oki, Eiji
    Saeki, Hiroshi
    Sadanaga, Noriaki
    Kusumoto, Tetsuya
    Touyama, Tetsuo
    Kimura, Masami
    Baba, Hideo
    Akagi, Yoshito
    Shirouzu, Kazuo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (02) : 335 - 343
  • [15] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
  • [16] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [17] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [18] Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer
    Gilcrease, G. Weldon
    Stenehjem, David D.
    Wade, Mark L.
    Weis, John
    McGregor, Kimberly
    Whisenant, Jonathan
    Boucher, Kenneth M.
    Thorne, Kelli
    Orgain, Nicole
    Garrido-Laguna, Ignacio
    Sharma, Sunil
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 482 - 489
  • [19] A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902)
    Takeuchi, Masaaki
    Ogata, Yutaka
    Tanaka, Takaho
    Kaibara, Atsushi
    Emi, Yasunori
    Saeki, Hiroshi
    Oki, Eiji
    Sadanaga, Noriaki
    Kusumoto, Tetsuya
    Touyama, Tetsuo
    Matsushita, Hiroo
    Shimokawa, Mototugu
    Baba, Hideo
    Shirouzu, Kazuo
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [20] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
12345